Peptide Field Book

Reading settings

Choose a comfortable text size and appearance. Your choices are saved on this device.

Eloralintide

Experimental appetite shot for weight loss

Eli Lilly, LY3841136

Match every finding to its exact substance, formulation, route and study population. A related molecule or approved medicine does not validate a catalog vial.

Human / product-specific records · Mechanistic / indirect records
Explore the evidenceWhy people take it
Compare this compoundRead original sources Community reports
Schematic illustration · View structure evidence

Simplified drawing of a chain of 37 amino acids

At a glance

Why people take it. And what backs it up.

  1. Lose weight

    Early human studies

    Mostly taken by trial volunteers, plus some gray-market users, to lose weight; in a 48-week trial, top doses cut weight about 20%.

    Sources (4)

  2. Break a weight-loss stall

    Company trial results not yet published

    Gray-market users add it to tirzepatide or retatrutide for stronger appetite control, often to break a plateau; Lilly is now testing a tirzepatide pairing.

    Sources (4)

Evidence briefing

Sources checked

What the sources support.

Eloralintide (LY3841136) is an investigational selective amylin agonist. A randomized 48-week phase 2 trial in 263 adults reported dose-dependent weight loss; phase 3 development is underway, with no approved product.

Keep in mind

Phase 2 excluded type 2 diabetes and enrolled a modest, mostly White population; long-term benefit and safety remain unsettled.

Identity and research status reviewRead the original sources

The research. What’s been studied.

All from early human studies

TapClick a dotted word to see what it means.

  • Strong weight loss

    Up to about 20% average weight loss at 48 weeks in a trial, large for a drug acting on receptors alone.

  • Appetite control

    Increases fullness and slows digestion by mimicking amylin.

  • Once-weekly dosing

    Engineered to last a week between injections.

What do these labels mean?
  • Human evidence: approved-drug data or larger human studies, within the populations and uses studied.
  • Early human studies: small, preliminary or limited human studies.
  • Animal & lab studies: animal or laboratory findings that do not establish effects in people.
  • Unverified: a proposed use or claim without verified supporting clinical evidence.
How each claim was reviewed (3)

Reported effects and evidence.

A citation may support, qualify or correct a claim. Read the study scope; a laboratory result is not an established benefit in people. Each review covers a claim as it was first collected; the tiles above show the collection’s current wording.

  1. Human phase 2 RCT

    Review of “Strong weight loss”

    A 48-week phase 2 trial reported up to approximately 20% mean weight loss, versus 0.4% with placebo, under its efficacy estimand.

    Limitations and applicability. The highest mean reductions were efficacy-estimand results in adults without diabetes; do not promise an individual outcome.

    Original collected claim and review history

    Original title: Strong weight loss

    Up to about 20% average weight loss at 48 weeks in a Phase 2 trial, large for a drug acting on amylin receptors alone.

    Original headline statistic: Up to about 20%

    Original label: early. Preserved for traceability; the reviewed wording above qualifies this record.

    Record eloralintide:benefit:1 · Annotated 2026-10-01 · Review method

  2. Mechanistic; direct endpoint unverified

    Review of “Appetite control”

    Eloralintide is an investigational selective amylin-receptor agonist; appetite and digestion mechanisms need direct supporting measurements.

    Limitations and applicability. Trial verifies selective amylin-receptor agonism, not the exact asserted fullness/digestion endpoints.

    Original collected claim and review history

    Original title: Appetite control

    Increases fullness and slows digestion by mimicking amylin.

    Original label: early. Preserved for traceability; the reviewed wording above qualifies this record.

    Record eloralintide:benefit:2 · Annotated 2026-10-01 · Review method

  3. Human investigational schedule

    Review of “Once-weekly dosing”

    Investigators evaluated eloralintide with once-weekly administration in a phase 2 trial.

    Limitations and applicability. Once-weekly use was a trial design feature, not a demonstrated clinical benefit or approved regimen.

    Original collected claim and review history

    Original title: Once-weekly dosing

    Engineered to last a week between injections.

    Original label: early. Preserved for traceability; the reviewed wording above qualifies this record.

    Record eloralintide:benefit:3 · Annotated 2026-10-01 · Review method

The research in detail

Evidence category

Human trials, not approved

A published randomized Phase 2 trial in 263 adults found dose-dependent weight reductions over 48 weeks, reaching about 20% in the highest-dose groups in the efficacy analysis. Phase 3 studies have started. Eloralintide remains investigational.

Evidence is assessed claim by claim above. Regulatory approval, study design, findings and relevance are separate questions; there is no single evidence score.

Risks and unknowns. What to know first.

Collected cautions follow. These are not an exhaustive or independently validated safety assessment; claim references do not automatically support every caution.

  • Nausea, vomiting and fatigue in trials, mostly mild to moderate and dose-related.

What people report

Read this first: what “research use only” means

Published dosing records. What the trials used.

Historical label and trial records for the named product, route, population and indication. These records are not a personal schedule or a validated regimen for a catalog vial. Source attribution does not establish applicability.

Phase 2 trial

Phase 2 trial in adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes (The Lancet, 2025)

Long-termClinical trial

Source: Billings et al., The Lancet, 2025

How
Injection under the skin
How often
Once a week
How long
48 weeks in the trial

Dose, step by step

  1. Weeks 1–4 3 mg
  2. Weeks 5–8 6 mg
  3. Week 9 on 9 mg

Limit. Highest dose tested: 9 mg once a week.

  • Other groups: 1, 3, 6 or 9 mg from the first dose with no ramp, or 6 mg for 20 weeks and then 9 mg.
  • Of the three groups that reached 9 mg, nausea was least common with this ramp (25%, versus 33% when starting at 9 mg and 54% with 6 mg then 9 mg).

These doses were tested in clinical trials under medical supervision. They aren’t approved for use, and a research vial is not the product that was tested.

Community protocols. Reported online. Not clinically validated.

Community reports Collection date: 30 Sep 2026

Grey-market eloralintide only appeared in mid-2026, and no settled protocol exists yet. The few reports describe starting at about 0.5–1 mg once a week on top of tirzepatide or retatrutide, with some pointing to Lilly’s trial steps (1.5, 3, 6 and 9 mg) as the thing to copy.

Not testedFrequently encountered in reviewed sources

Low start on top of a GLP-1 drug

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
0.5–1 mg
How often
Once a week (one user split it into 0.5 mg every 4 days)
Route
Injection under the skin
Timing
Some inject it on the same day as their retatrutide or tirzepatide
Mixing
Sold as 10 mg (also 20 mg) research vials, often through “group buys”
  • Users treat it as a stronger alternative to cagrilintide (“cagri on steroids”) to break a weight-loss stall.
  • Users describe a long half-life, with nausea peaking a few days after the shot.
Sources (4)

Not testedSometimes seen

Copying the trial steps

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
1.5 mg, then 3 mg, 6 mg and 9 mg (some start directly at 3–6 mg)
How often
Once a week
Route
Injection under the skin
Ramp
Trial participants describe 4 weeks at each step
  • Mostly quoted as a reference point; few grey-market users report actually reaching 6–9 mg.
Sources (3)
Show all 3 protocolsShow fewer protocols

Not testedFringe

Daily dosing

Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.

Frequency labels describe this collection, not a measured population. Contradictory records remain available.

Details and sourcesHide details
Dose
1 mg
How often
Every day
Route
Injection under the skin
  • A single report; eloralintide is designed as a once-a-week drug.
Sources (1)

Where the numbers come from

No established grey-market protocol: a June 2026 poster could not find one. Users either borrow the dose steps from Lilly’s trials (1.5, 3, 6 and 9 mg) or start lower, at 0.5–1 mg, by analogy with cagrilintide.

Research notes

Very new and thinly documented: the first grey-market reports date from May–June 2026, and most posts in r/Eloralintide come from trial participants. One enthusiastic “review” names a vendor and may be promotional. No clinic, vendor protocol, practitioner, podcast or news source on grey-market dosing was found, and no regulator warning naming eloralintide was found.

Measurement basics and calculator

Explore vial arithmetic

What it is. In plain English.

Eli Lilly’s experimental amylin-based weight-loss drug.

A once-weekly amylin receptor developed by Eli Lilly.

It is designed to activate amylin receptors, which are involved in fullness and stomach emptying. Weight-loss findings come from clinical trials of this investigational drug.

Reviewed 2026-10-01.

Structure. Nothing to show yet.

No experimental 3D structure of eloralintide is in the .

Searches by name and by its code, LY3841136, found nothing, and none of the 32 calcitonin and amylin receptor entries contains it. PubChem lists it without a sequence, so it couldn’t be searched that way.

Checked 30 Sep 2026.

Specs. The facts at a glance.

Type
amylin agonist
Sold as
  • Eloralintide 10 mg
Regulatory status
Investigational. Not approved.
Also known as
Eli Lilly, LY3841136

Sources. What this page rests on.

Every source behind this page, with what it says and when it was checked, is in the Source library.

Eloralintide in the Source library

Original overview and research notes · annotated 2026-10-01

Historical collection text. Read alongside the claim corrections above; identity or evidence qualifications may supersede this wording.

Experimental amylin-based weight loss

Eli Lilly’s experimental amylin-based weight-loss drug.

A once-weekly amylin receptor agonist developed by Eli Lilly.

Like cagrilintide, it mimics amylin to increase fullness and slow digestion, acting through the brainstem rather than the pathway.

A Phase 2 trial reported in late 2025 found up to about 20% weight loss at 48 weeks, a large effect for a drug acting on amylin receptors alone. Phase 3 trials have started.

Original status record: Investigational. Not approved.

More in Weight & metabolism.

Glossary

Agonist

A molecule that activates a receptor, mimicking the body’s own signal. An antagonist blocks it.

Full glossary

Glossary

GLP-1 / GIP

Gut hormones released after eating that raise insulin and reduce appetite. The basis of today’s weight-loss drugs.

Full glossary

Glossary

Amylin

A hormone released with insulin that signals fullness through the brainstem. The target of cagrilintide and eloralintide.

Full glossary

Glossary

Phase 1 / 2 / 3

Stages of human drug testing: safety in a few people, then effectiveness in hundreds, then large confirmatory trials in thousands. Most compounds fail along the way.

Full glossary

Glossary

Protein Data Bank (PDB)

The free worldwide archive of 3D structures of proteins and other molecules measured in experiments. Each entry has a four-character code, like 7KI0.

Full glossary